^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersTEST:LiquidGx™
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Nucleos HealthcareType:
Laboratory Developed Test
LiquidGx™ is a non-invasive cancer test for selecting relevant solid tumor therapies
Cancer:
Solid Tumor
Gene:
AKT1 (V-akt murine thymoma viral oncogene homolog 1), ALK (Anaplastic lymphoma kinase), BRAF (B-raf proto-oncogene), EGFR (Epidermal growth factor receptor), HER-2 (Human epidermal growth factor receptor 2), HRAS (Harvey rat sarcoma viral oncogene homolog)
See More ...
AKT1 (V-akt murine thymoma viral oncogene homolog 1), ALK (Anaplastic lymphoma kinase), BRAF (B-raf proto-oncogene), EGFR (Epidermal growth factor receptor), HER-2 (Human epidermal growth factor receptor 2), HRAS (Harvey rat sarcoma viral oncogene homolog), KIT (KIT proto-oncogene, receptor tyrosine kinase), KRAS (KRAS proto-oncogene GTPase), MAP2K1 (Mitogen-activated protein kinase kinase 1), MET (MET proto-oncogene, receptor tyrosine kinase), NRAS (Neuroblastoma RAS viral oncogene homolog), PDGFRA (Platelet Derived Growth Factor Receptor Alpha), PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha), PTEN (Phosphatase and tensin homolog), RET (Ret Proto-Oncogene), ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS), TP53 (Tumor protein P53)
Drug:
Alecensa (alectinib), Alunbrig (brigatinib), Mekinist (trametinib), Tafinlar (dabrafenib), Xalkori (crizotinib), Zelboraf (vemurafenib), Zykadia (ceritinib)
Method:
Next-Generation Sequencing (NGS)
